Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism

Nature

Volumn 531, Issue 7596, 2016, Pages 651-655

  Yang, Wei ^a   Bai, Yibing ^a   Xiong, Ying ^a   Zhang, Jin ^a   Chen, Shuokai ^a   Zheng, Xiaojun ^b   Meng, Xiangbo ^a   Li, Lunyi ^a   Wang, Jing ^c   Xu, Chenguang ^c   Yan, Chengsong ^a   Wang, Lijuan ^a   Chang, Catharine C Y ^d   Chang, Ta Yuan ^d   Zhang, Ti ^e   Zhou, Penghui ^f   Song, Bao Liang ^g   Liu, Wanli ^c   Sun, Shao Cong ^h   Liu, Xiaolong ^a   Li, Bo Liang ^a   Xu, Chenqi ^a,i   more..

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c TSINGHUA UNIVERSITY   (China)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^g WUHAN UNIVERSITY   (China)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ SHANGHAITECH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AVASIMIBE; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHOLESTEROL ACYLTRANSFERASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; L SELECTIN; MEMBRANE LIPID; MESSENGER RNA; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ACAT1 PROTEIN, MOUSE; ACETIC ACID DERIVATIVE; ACETYL COENZYME A ACETYLTRANSFERASE; CHOLESTEROL; LYMPHOCYTE ANTIGEN RECEPTOR; SULFONIC ACID DERIVATIVE;

ANTIBODY; CANCER; CELLS AND CELL COMPONENTS; INHIBITOR; METABOLISM; RODENT; STEROL; TUMOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEMBRANE; CELL SURVIVAL; CELL VIABILITY; CHOLESTEROL ESTERIFICATION; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; EX VIVO STUDY; IMMUNE RESPONSE; IMMUNOLOGICAL SYNAPSE; IMMUNOPOTENTIATION; IN VIVO STUDY; INTERFERON PRODUCTION; LEWIS CARCINOMA; LISTERIOSIS; LUNG METASTASIS; LYMPHOCYTE HOMING; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; DEFICIENCY; DRUG EFFECTS; ESTERIFICATION; FEMALE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METABOLISM; PATHOLOGY; PROCEDURES;

MUS;

ACETATES; ACETYL-COA C-ACETYLTRANSFERASE; ANIMALS; ATHEROSCLEROSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL MEMBRANE; CHOLESTEROL; ESTERIFICATION; FEMALE; IMMUNOLOGICAL SYNAPSES; IMMUNOTHERAPY; MALE; MELANOMA; MICE; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SULFONIC ACIDS;

EID: 84962381625     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature17412     Document Type: Article

References (38)

1. Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nature Rev. Cancer 12, 298-306 (2012).
2. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
3. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480-489 (2011).
4. Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74-80 (2015).
5. Chang, T. Y., Chang, C. C., Ohgami, N. & Yamauchi, Y. Cholesterol sensing, trafficking, and esterification. Annu. Rev. Cell Dev. Biol. 22, 129-157 (2006).
6. Chang, T. Y., Li, B. L., Chang, C. C. & Urano, Y. Acyl-coenzyme A:cholesterol acyltransferases. Am. J. Physiol. Endocrinol. Metab. 297, E1-E9 (2009).
7. Pal, P., Gandhi, H., Giridhar, R. & Yadav, M. R. ACAT inhibitors: the search for novel cholesterol lowering agents. Mini Rev. Med. Chem. 13, 1195-1219 (2013).
8. Yao, S., Zhu, Y. & Chen, L. Advances in targeting cell surface signalling molecules for immune modulation. Nature Rev. Drug Discov. 12, 130-146 (2013).
9. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61 (2015).
10. Xu, C. et al. Regulation of T cell receptor activation by dynamic membrane binding of the CD3e cytoplasmic tyrosine-based motif. Cell 135, 702-713 (2008).
11. Shi, X. et al. Ca2+ regulates T-cell receptor activation by modulating the charge property of lipids. Nature 493, 111-115 (2013).
12. Gagnon, E., Schubert, D. A., Gordo, S., Chu, H. H. & Wucherpfennig, K. W. Local changes in lipid environment of TCR microclusters regulate membrane binding by the CD3e cytoplasmic domain. J. Exp. Med. 209, 2423-2439 (2012).
13. Molnár, E. et al. Cholesterol and sphingomyelin drive ligand-independent T-cell antigen receptor nanoclustering. J. Biol. Chem. 287, 42664-42674 (2012).
14. Schamel, W. W. et al. Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response. J. Exp. Med. 202, 493-503 (2005).
15. Zech, T. et al. Accumulation of raft lipids in T-cell plasma membrane domains engaged in TCR signalling. EMBO J. 28, 466-476 (2009).
16. Kidani, Y. et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nature Immunol. 14, 489-499 (2013).
17. Leon, C., Hill, J. S. & Wasan, K. M. Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) inhibitors as hypolipidemic and antiatherosclerosis drugs. Pharm. Res. 22, 1578-1588 (2005).
18. Chang, C. C. et al. Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J. Biol. Chem. 275, 28083-28092 (2000).
19. Ikenoya, M. et al. A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis 191, 290-297 (2007).
20. Tobert, J. A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Rev. Drug Discov. 2, 517-526 (2003).
21. Cenedella, R. J. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids 44, 477-487 (2009).
22. MacIver, N. J., Michalek, R. D. & Rathmell, J. C. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31, 259-283 (2013).
23. Santori, F. R. et al. Rare, structurally homologous self-peptides promote thymocyte positive selection. Immunity 17, 131-142 (2002).
24. Lillemeier, B. F. et al. TCR and Lat are expressed on separate protein islands on T cell membranes and concatenate during activation. Nature Immunol. 11, 90-96 (2010).
25. Beal, A. M. et al. Kinetics of early T cell receptor signaling regulate the pathway of lytic granule delivery to the secretory domain. Immunity 31, 632-642 (2009).
26. Huttunen, H. J. & Kovacs, D. M. ACAT as a drug target for Alzheimer's disease. Neurodegener. Dis. 5, 212-214 (2008).
27. Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P. & Wolchok, J. D. Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185-202 (2014).
28. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer 12, 252-264 (2012).
29. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62-68 (2015).
30. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
31. Cao, Y. et al. LKB1 regulates TCR-mediated PLCγ1 activation and thymocyte positive selection. EMBO J. 30, 2083-2093 (2011).
32. Guo, Z. Y., Lin, S., Heinen, J. A., Chang, C. C. & Chang, T. Y. The active site His-460 of human acyl-coenzyme A:cholesterol acyltransferase 1 resides in a hitherto undisclosed transmembrane domain. J. Biol. Chem. 280, 37814-37826 (2005).
33. Das, A., Goldstein, J. L., Anderson, D. D., Brown, M. S. & Radhakrishnan, A. Use of mutant 125I-perfringolysin O to probe transport and organization of cholesterol in membranes of animal cells. Proc. Natl Acad. Sci. USA 110, 10580-10585 (2013).
34. Rossy, J., Owen, D. M., Williamson, D. J., Yang, Z. & Gaus, K. Conformational states of the kinase Lck regulate clustering in early T cell signaling. Nature Immunol. 14, 82-89 (2013).
35. Brian, A. A. & McConnell, H. M. Allogeneic stimulation of cytotoxic T cells by supported planar membranes. Proc. Natl Acad. Sci. USA 81, 6159-6163 (1984).
36. Grakoui, A. et al. The immunological synapse: a molecular machine controlling T cell activation. Science 285, 221-227 (1999).
37. Liu, W., Won Sohn, H., Tolar, P., Meckel, T. & Pierce, S. K. Antigen-induced oligomerization of the B cell receptor is an early target of FcγRIIB inhibition. J. Immunol. 184, 1977-1989 (2010).
38. Jenkins, M. R., Tsun, A., Stinchcombe, J. C. & Griffiths, G. M. The strength of T cell receptor signal controls the polarization of cytotoxic machinery to the immunological synapse. Immunity 31, 621-631 (2009).